Genmab and AbbVie reported a 51% reduction in the risk of disease progression or death in a clinical trial. No further details were immediately available.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
